Page mackup-Final.qxd Original article: Cardio-protective properties of Momordica charantia in Albino Rats Sheriff OL1, Yusuf FA2 Abstract: Momordica charantia, commonly known as bitter gourd, is used as a vegetable by the Asian communi- ty in Africa. It is frequently used as an anti-diabetic herb for the management of disease in the Ayurvedic system of Medicine. This present study was aimed at evaluating possible cardio-protective properties of M. charantia by determining its effect on blood cholesterol levels in albino rats. The study involved 25 rats and they were divided into 5 groups each comprising of 5 rats. The aqueous extract of M. Charantia was administered orally with syringes and cannula to 4 groups at different doses (80mg/kg, 100mg/kg, 120mg/kg and 140mg/kg body weights per day, respectively) and the last group served as the control and were given drug vehicle (normal saline) only. After two weeks of administration, the 25 rats were sacrificed and blood samples were collected and assayed for total blood cholesterol, triglyceride, high- density lipoprotein and low-density lipoprotein levels. Results indicated that M. charantia plant extract increased significantly (P<0.05) the low density lipoprotein levels in the experimental group B (100mg/kg), and significantly reduced low density lipoprotein levels (P<0.05) in the experimental group A (80mg/kg), when compared to the control group. This study showed that M. charantia plant extract has cardio-protective properties by its dose-dependent effects on blood cholesterol. Key Words: momordica charantia, cardio-protective, orally, dose-dependent, cholesterol Introduction Finding healing powers in plants is an ancient idea. People on all continents have long applied poul- tices and imbibed infusions of hundreds, if not thousands, of indigenous plants, dating back to prehistory 1 . It is estimated that there are 250,000 to 500,000 species of plants on Earth 2 . Relatively small per- centages (1 to 10%) of these are used as foods by both humans and other animal species. It is possi- ble that even more are used for medicinal purpos- es3. Momordica charantia (MC), a member of the Cucurbitaceae family, is known as bitter melon, bitter gourd, balsam pear, karela, and pare. It grows in tropical areas of the Amazon, East Africa, Asia, India, South America, and the Caribbean and is used traditionally as both food and medicine. Several studies revealed that this plant has anti- ulcer, anti-diabetic, antifungal, anti-leukemic, anti- protozoan, antibacterial, anti-fertility, antiviral, and hypoglycemic effects 3, 4, 5 . Cholesterol is a waxy steroid metabolite found in the cell membrane and transported in the blood plasma of animals 6 . It is an essential structural component of mammalian cell membranes and also an important component for the manufacture of bile acids, steroid hormones and fat soluble vita- mins 7 . Cholesterol, being amphipathic, is trans- ported in the surface monolayer of the lipoprotein particle. There are several lipoproteins within the blood; these include chylomicrons, very-low density lipoproteins (VLDL), intermediate-density lipopro- teins (IDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL). The lipoprotein particles are molecular addresses that determine the start- and endpoint for cholesterol transport. The more cholesterol and less protein a lipoprotein has, the less dense it is. The LDL molecules are the major carriers of cholesterol in the blood8. Studies have shown that having large numbers of HDL particles correlates with better health out- comes; in contrast to having small numbers which has been associated with atheromatous disease pro- gression within the arteries 2 . Low HDL cholesterol is an independent cardiovascular risk factor. 1. Ojulari Lekan Sheriff, Department of Physiology, University of Ilorin. 2. Yusuf FA, Department of Physiology, University of Ilorin. Corresponds to: Ojulari Lekan Sheriff, Department of Physiology, University of Ilorin, Nigeria. e- mail: Ojulari@unilorin.edu.ng Bangladesh Journal of Medical Science Vol. 12 No. 03 July’13 291 Clinical evidence also indicates that a low level of HDL is a major risk factor of atherosclerosis. Raising HDL significantly reduces this risk, mak- ing HDL levels an important target of treatment, particularly in patients with pre-existing athero- sclerosis. Both LDL and HDL cholesterol levels are impor- tant factors to determining the risk for coronary artery disease. An increase in coronary artery dis- ease is associated with increased LDL and decreased HDL cholesterol levels 10 . As high LDL and low HDL are both independent risk factors for heart disease, the ratio of the two numbers is a useful tool to evaluate cardiovascular risk. Numerous natural substances have been shown to positively affect the HDL/LDL ratio. Triglycerides are esters composed of a glycerol bound to three fatty acids. They are major compo- nents of VLDL and chylomicrons and play an important role in metabolism as energy sources and transporters of dietary fat. High levels in the bloodstream have been linked to some cardiovas- cular diseases 11 . Despite the widespread usage of this plant in folk medicine in the management of many health con- ditions, only a few, nonrandomized clinical studies have investigated the effects of MC in humans 12, 13, 16, 15 . It is therefore crucial to conduct more studies which will shed more light on its other physiolog- ical effects. This study therefore seeks to assess possible cardio-protective properties of MC by determining its effect on the blood cholesterol level in rats. Materials and methods: Experimental protocol: Twenty-five albino rats (mean weight 150-180g) were maintained under standard laboratory conditions and were allowed free access to food and water ad libitum. Animals were divided randomly into five groups. Control (distilled water): group A, MC (80mg/kg for 14 days); group B, MC (100mg/kg for 14 days), group C, MC (120mg/kg for 14 days); and group D, MC (140mg/kg for 14 days). Extract, route and blood collection: The leaves of MC were aired and dried and milled into pow- der. 1.5 kg of the sample was percolated in 13 liters of water for about 48 hours, after which it was filtered and evaporated using water bath to give about 220g of a dark solid extract which was stored at 40C temperature before physiological studies were made before oral administration. After two weeks of administration, the 25 rats were sacrificed by cervical dislocation after being anaesthetized with chloroform. Blood samples were obtained through cardiac puncture. Statistical analysis: All results were expressed as mean±SEM. Data was analysed by one-way analysis of variance (ANOVA) and Duncan New Multiple Range Test (DMRT). Differences in means were considered significant at P<0.05. All analysis was performed using SPSS Version 17. Results Effect of Momordica charantia (MC) on total cho- lesterol: Administration of MC caused insignificant changes in the total cholesterol levels in experi- mental groups after 14 days of treatment when compared to the control group (fig1). Effect of Momordica charantia on Triglyceride: The effect of MC on triglyceride is shown in fig 2. Triglyceride levels for the treated groups A, B, C and D (1.4, 1.6, 1.2,1.6 mmol/L) were not sig- nificantly different from the compared controls after 14 days of treatment. Effect of Momordica charantia on HDL-C: The effect of MC on HDL-C was depicted in fig 3. Administration of MC had no significant impact on HDL as evidenced by measured values of 0.5, 1.0, 0.5, 1.0 mmol/L for groups A, B, C, and D respectively. Effect of Momordica charantia on LDL-C: The measured levels of LDL-C showed significant changes in the groups A (80mg/kg) and B (100mg/kg). It was significantly lowered in group A (1.1 mmol/L) and signicantly raised in group B, when compared with the control. The other exper- imental groups showed no significant changes when compared to the control (fig 4). Discussion The study revealed insignificant changes in total cholesterol level in MC administered rats as com- Cardio-protective properties of Momordica charantia in Albino Rats 292 pared with controls. The blood triglyceride levels and HDL-C levels exhibited insignificant increases and decreases while the LDL-C levels showed sig- nificant changes at different doses of administra- tion. These results suggest that MC, when admin- istered orally and at doses employed, has a signif- icant dose/duration modulating effect on blood cholesterol levels. The normal total cholesterol levels seen in our study indicates that MC possibly has no effect on total cholesterol levels. This is contrary to findings of Chaturvedi et al; 2004 16 , who reported that rats exposed to MC for 30 days had significantly low- ered total blood cholesterol levels. This differing result is probably due to the difference in duration and dose of administration. It therefore appears that the effect of MC on total cholesterol levels in rats is both dose and duration dependent, with the duration factor being more pronounced. The triglyceride level usually provides a useful index for cardiovascular risk assessment in exper- imental studies. The observed levels in control and experimental rats suggest that the administration of MC at doses and duration used had no effect on blood levels. This is contrary to results by Chatuvedi and Ahmed et al in which triglyceride levels showed a dose-dependent response to the MC extract 16,17 . It may therefore be plausible to note that the levels of blood triglyceride may be associated with the insensitivity of triglyceride to MC in-vivo, which is likely due to the short dura- tion of treatment. The LDL-C level in this study showed significant increase and decrease at differing doses. Experimental rats in group B showed significantly lowered LDL-C levels. This corresponds to results observed in studies carried out by Chaturvedi (2005) in which LDL-C levels where found to be low, even in the groups on 80mg/kg dose 18 . This is probably due to the lowering effect of MC on apolipoprotein B (Apo B) secretion by the liver, with a consequent reduction in LDL-C levels 19 . Experimental rats in group B showed significantly increased LDL-C blood levels. This also corre- sponds to results in studies by Chaturvedi in which LDL-C levels increased significantly after admin- istration of higher doses of MC 18 . Serum lipids are important markers for overall car- diovascular risk. According to the Centres for Disease Control and Prevention (CDC), an esti- mated 106.9 million American adults have elevat- ed total blood cholesterol levels; approximately 47.9 percent of men and 49.7 percent of women 20 . The World health Organization states that 18 per- cent of stroke events and about 56 percent of heart disease is attributable to total cholesterol levels above 3.2 mmol/l, which amounts to about 4.4 million deaths 21 . According to the lipid hypothesis, abnormal cho- Sheriff OL, Yusuf FA 293 Groups Mean (mg/ml) S.E.M. P-value Control 2.4 2.4 ± 0.2 A (80mg/kg) 3.2 3.2 ± 0.3 P > 0.05 B (100mg/kg) 2.5 2.5 ± 0.3 P > 0.05 C (120mg/kg) 2.6 2.6 ± 0.2 P > 0.05 D (140mg/kg) 2.1 2.1 ± 0.2 P > 0.05 Table 1: Total Cholesterol level in Control and Experimental rats Table 2: Triglyceride level in Control and Experimental rats Groups Mean (mg/ml) S.E.M. P-value Control 1.4 1.4 ± 0.1 A (80mg/kg) 1.4 1.4 ± 0.2 P > 0.05 B (100mg/kg) 1.6 1.6 ± 0.1 P > 0.05 C (120mg/kg) 1.2 1.2 ± 0.2 P > 0.05 D (140mg/kg) 1.6 1.6 ± 0.2 P > 0.05 Groups Mean (mg/ml) S.E.M. P-value Control 0.8 0.8 ± 0.1 A (80mg/kg) 0.5 0.5 ± 0.2 P > 0.05 B (100mg/kg) 1.0 1.0 ± 0.1 P > 0.05 C (120mg/kg) 0.5 0.5 ± 0.1 P > 0.05 D (140mg/kg) 1.0 1.0 ± 0.2 P > 0.05 Table 3: High-density lipoprotein cholesterol (HDL-C) in Control and Experimental rats Groups Mean (mg/ml) S.E.M. P-value Control 1.3 1.3 ± 0.1 A (80mg/kg) 1.1 1.1 ± 0.4 P ? 0.05 B (100mg/kg) 1.4 1.4 ± 0.2 P ? 0.05 C (120mg/kg) 1.0 1.0 ± 0.2 P > 0.05 D (140mg/kg) 1.2 1.2 ± 0.1 P > 0.05 Table 4: Low-density lipoprotein cholesterol (LDL-C) in Control and Experimental rats Cardio-protective properties of Momordica charantia in Albino Rats 294 lesterol levels (hypercholesterolemia)—that is, higher concentrations of LDL and lower concen- trations of functional HDL, are strongly associated with cardiovascular disease 22 . High levels of cho- lesterol in blood, depending on how it is transport- ed within lipoproteins, are strongly associated with progression of atherosclerosis. LDL molecules are the major carriers of cholesterol in blood. When there is high level of cholesterol, the molecules are oxidized and taken up by macrophages, which become engorged and form foam cells. These cells often become entrapped in the walls of blood ves- sels and contribute to atherosclerotic plaque forma- tion. These plaques are the main causes of heart attacks, strokes and other serious medical prob- lems 19 . As high LDL and low HDL are both independent risk factors for heart disease, the ratio of the two numbers is a useful tool to evaluate cardiovascular risk 11 . In fact, one study showed that a 1 percent greater LDL value is associated with slightly more than a 2 percent increase in coronary artery disease over 6 years, and a 1 percent lower HDL value is associated with a 3 to 4 percent increase in coro- nary artery disease, even at total cholesterol levels less than 200 mg/dl. Additionally, low HDL levels are associated with increased heart attacks and death from coronary artery disease 10 . Numerous natural substances have also been shown to posi- tively affect the HDL/LDL ratio 23-24 . The HDL/LDL ratio which is a biomarker for car- diovascular disease was increased in rats given MC at longer duration of treatment. This was evi- denced by the significant decrease in LDL levels at lower doses of administration of the extract. This development was shown to be mostly duration dependent and it appears that longer duration of treatment may play an important role in the devel- opment of higher HDL/LDL ratios. In conclusion, administration of MC, at doses and duration employed in this study, had dose-depend- ent cardio-protective properties via its effect on the blood cholesterol levels. However, there is an indi- cation that higher doses should be discouraged. Sheriff OL, Yusuf FA 295 References: 1) Stockwell, C: Nature's pharmacy. Century Hutchinson Ltd., London, United Kingdom. 1988 2) Borris RP. Natural products research: perspec- tives from a major pharmaceutical company. J Ethnopharmacol. 1996; 51:29–38. h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / 0 3 7 8 - 8741(95)01347-4 3) Moerman DE. An Analysis of the Food Plants and Drug Plants of Native North America. Journal of Ethnopharmacology1996; 52: 1-22. h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / 0 3 7 8 - 8741(96)01393-1 4) Yesilada E, Gurbuz I and Shibata H. Screening of Turkish antiulserogenic folk remedies for anti Helicobacter pylori activity. J Ethnopharmacol 1999; 66: 289-93. h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / S 0 3 7 8 - 8741(98)00219-0 5) Girini MM. Effect of graded doses of Momordica charantia seed extract on rat sperm: scanning electron microscope study. J. Basic Clin. Physiol. Pharmacol 2005; 1 6 ( 1 ) : 5 3 - 6 6 . h t t p : / / d x . d o i . o r g / 1 0 . 1515/JBCPP.2005.16.1.53PMid:16187486 6) Emma Leah : "Cholesterol". Lipidomics Gateway.doi:10.1038/lipidmaps.2009.3. http://www.lipidmaps.org/update/2009/09050 1 / f u l l / l i p i d m a p s . 2 0 0 9 . 3 . h t m l . http://dx.doi.org/10.1038/lipidmaps.2009.3 7) Olson RE. Discovery of the lipoprotein, their role in fat transport and their significance as risk factors. J. Nutri. 1998; 128(2): 4395- 4435. 8) Tymoczko JL, Stryer B and Berg JM. Biochemistry. San Francisco: W.H. Freeman. 2002; 726–727. 9) Gordon DJ, Probsfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Bangdiwala S, and Tyroler HA. High- density lipoprotein cholesterol and cardiovas- cular disease. Four prospective American stud- ies. Circulation 1989; 79 (1): 8-15. http://dx.doi.org/10.1161/01.CIR.79.1.8 PMid:2642759 10) Wilson PW. High-density lipoprotein, low- density lipoprotein and coronary artery dis- ease. Am J Cardiol 1990; 66(6):7A-10A. h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / 0 0 0 2 - 9149(90)90562-F 11) American Heart Association. Cholesterol Statistics from National Health and Nutrition Examination Survey (NHANES), 1999-2004, National Center for Health Statistics and the NHLBI. Available at: http://www.american- heart.org/presenter. 12) Basch E, Gabardi S and Ulbricht C. Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health Syst Pharm 2003; 60: 356-359.PMid:12625217 13) Leatherdale BA, Panesar RK, Singh G, Atkins TW, Bailey CJ and Bignell AH. Improvement in glucose tolerance due to Momordica charan- tia (karela). Br Med J (Clin Res Ed) 1981; 282 : 1 8 2 3 . h t t p : / / d x . d o i . o r g / 1 0 . 1136/bmj.282.6279.1823 14) Stivastava Y, Venkatakishna- Bhatt H and Verma Y. Antidiabetic and adaptogenic prop- erties of Momordica charantia extract. An experimental and clinical evaluation. Phytother Res 1993; 7:285-289.http://dx.doi.org/10. 1002/ptr.2650070405 15) Welihinda J, Karunanayake EH, Sheriff MHH, and Jayasinghe KSA. Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes. Journal of Ethnopharmacology 1986; 17(3): 277-282.http://dx.doi. org/10.1016/0378-8741(86)90116-9 16) Chaturvedi P, George S, Miliganyo M and Trpathi Y. Effect of M. Charantia on lipid pro- file and oral glucose tolerance in diabetic rats. Phytother res 2004; 18:954-9.http://dx.doi. org/10.1002/ptr.1589PMid:15597317 17) Ahmed I, Lakhani MS, Gillett M, John A and Raza H. Hypotriglyceridemic and hypocholes- terolemic effects of anti-diabetic Momordica charantia (karela) fruit extract in streptozo- Cardio-protective properties of Momordica charantia in Albino Rats 296 tocin-induced diabetic rats. Diabetes Res Clin Pract 2001; 51(3):155-61.http://dx.doi.org/ 10.1016/S0168-8227(00)00224-2 18) Chaturvedi P. Role of Momordica charantia in maintaining the normal levels of lipids and glu- cose in diabetic rats fed a high-fat and low-car- bohydrate diet. British Journal of Biomedical Science. 2005PMid:16196458 19) Umesh CS, Yadav K and Najma Z. Combined treatment of sodium orthovanadate and Momordica charantia fruit extract prevents alterations in lipid profile and lipogenic enzymes in alloxan diabetic rats. Baquer Molecular and Cellular Biochemistry 2005; 268(1-2): 111-120. http://dx.doi.org/10.1007/s11010-005-3703-y 20) Center for Disease Control and Prevention. Division for Heart Disease and Stroke Prevention Cholesterol Fact Sheet. Available at:http://www.cdc.gov/DHDSP/library/fs_cho lesterol.htm. 21) World Health Organization. Chronic disease risk factors. Available at: http://www.who.int/dietphysicalactivity/publi- cations/facts/riskfactors/en/index.html. 22) Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH and Witztum JL. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008; 31 (4): 811–22. http://dx.doi.org/ 10.2337/dc08-9018PMid:18375431 23. K Matira, ZF Dewan, TC Rehnuma, A Farhana, UN Zeba, S Shahin. Pre treatment by the crude and the n-hexane extract of Nigella sativa Linn. (Kalajira) alleviates diabetes mel- litus. Bangladesh Journal of Medical Science 2009; 8 (1-2): 5-9. doi: 10.3329/bjms. v8i1.3182 24. DC Nanjunda. Ethno-medico-botanical Investigation of Jenu Kuruba Ethnic Group of Karnataka State, India. Bangladesh Journal of Medical Science 2010: 09 (3): 161-169. DOI: 10.3329/bjms.v9i3.6479 Sheriff OL, Yusuf FA 297